# Comparative Safety and Efficacy of Two Rosacea Products in the Treatment of Facial Erythema of Rosacea

> **NCT02385240** · PHASE3 · COMPLETED · sponsor: **Padagis LLC** · enrollment: 552 (actual)

## Conditions studied

- Rosacea

## Interventions

- **DRUG:** Brimonidine Topical Gel, 0.33 percent (Perrigo)
- **DRUG:** Brimonidine Topical Gel, 0.33 percent (Reference)
- **DRUG:** Placebo gel

## Key facts

- **NCT ID:** NCT02385240
- **Lead sponsor:** Padagis LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-03
- **Primary completion:** 2015-12
- **Final completion:** 2015-12
- **Target enrollment:** 552 (ACTUAL)
- **Last updated:** 2021-10-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02385240

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02385240, "Comparative Safety and Efficacy of Two Rosacea Products in the Treatment of Facial Erythema of Rosacea". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02385240. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*